Thiophenes
United States Patent [1 1 Szente et al.  
 [4 1 Apr. 29, 1975 1 1 ,THIOPHEN&#39;ES [75] lnventors: Andre Szente; Joseph Hellerbach,  
 &#39; both of Basel, Switzerland [73] Assignee: Hoffman-La Roche Inc., Nutley,  
 [22] Filed: Aug. 22, 1973 [21] Appl. No.: 390,627  
 Mar. 2, 1973 [56] References Cited OTHER PUBLlCATlONS DellErba et al., Tetrahedron, V01. 21, pp. 1061-1066, (1965). Leandri et al., Chem. 21091-21092, (1961). Profft et al., Chem. Abst. Vol. 61, col. 8254-8256, (1964).  
 Abst., Vol. 55, col.  
 Primary ExaminerHarry l. Moatz Attorney, Agent, or FirmSamuel L. Welt; Jon S. Saxe; Gerald S. Rosen [57] ABSTRACT Compound represented by the formula wherein R represents lower alkyl, lower alkenyl, lower alkynyl, halo lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, loweralkylthio lower alkyl, lower alkylcarbonyl, halo lower alkylcarbonyl, lower alkanoyloxy lower alkyl, lower aroyloxy lower alkyl, pyridylcarbonyloxy lower alkyl, lower alkylaminocarbonyloxy lower alkyl or in which R, and R each represent hydrogen or lower alkyl or R and R together with the nitrogen atom to which they are attached represent a 3-, 5-, 6- or 7-membered saturated heterocyclic ring which, in the case of a 5-, 6- or 7-membered ring, may contain a further nitrogen atom or an oxygen or sulphur atom and may be substituted by lower alkyl or hydroxy lower alkyl and n stands for l, 2, 3 or 4, R represents hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy lower alkyl or hydroxy lower alkyl or R and R together with the nitrogen atom to which they are attached represent a 3-, 5-, 6- or 7-membered saturated heterocyclic ring which, in the case of a 5-, 6- or 7-membered ring, may contain a further nitorgen atom or an oxygen or sulphur atom and may be substituted by lower alkyl or hydroxy lower alkyl and R represents hydrogen or halogen or lower alkyl, provided that when R represents lower alkyl and R and R each represent hydrogen and the variable nitro group is present in the 5-position, then R represents lower alkyl containing 2 to 7 carbon atoms,  
 and pharmaceutically acceptable acid addition salts of those compounds described herein which are basic and thus amenable to forming acid addition salts having protozoacidal, bactericidal, anthelmintic and schistosomicidal activity are disclosed.  
 43 Claims, No Drawings THIOPHENES DETAILED DESCRIPTION OF THE INVENTION This invention relates to thiophene compounds having protozoacidal, bactericidal,:anthelmintic and schistosomicidal activity. The thiophene compounds of this invention are represented by the formula wherein R represents lower alkyl, lower alkenyl,  
 lower alkynyl, halo-lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, lower alkylthio lower in which R and R each represent hydrogen or lower alkyl or R and R together with the nitrogen atom to which they are attached represent a 3-, 5-, 6- or 7-membered saturated heterocyclic ring which, in the case of a 5-, 6- or 7-membered ring, may contain a further nitrogen atom or an oxygen or sulphur atom and may be substituted by lower alkyl or hydroxy lower alkyl and n stands for l, 2, 3 or 4, R represents hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy lower alkyl or hydroxy lower alkyl or R, and R together with the nitrogen atom to which they are attached represent a 3-, 5-, 6- or 7-membered saturated heterocyclic ring which, in the case of a 5-, 6- or 7-membered ring, may contain a further nitrogen atom or an oxygen or sulphur atom and may be substituted by lower alkyl or hydroxy lower alkyl and R represents hydrogen or halogen or lower alkyl, provided that when R represents lower alkyl and R and R each represent hydrogen and the variable nitro group is present in the 5-position, then R represents lower alkyl containing 2 to 7 carbon atoms, and pharmaceutically acceptable acid addition salts of those compounds described herein which are basic and thus amenable to forming acid addition salts.  
  As used herein, the term lower alkyl, alone or in combinations such as, for example, in lower alkoxy,&#34;  
 lower &#39;alkoxy lower alkyl, lower alkylcarbonyl, 6O  
 pyl, butyl, tertbutyl, pentyl and theglike. The terms lower alkenyl&#34; and lower alkynyl&#34; include branched-chain or straight-chain unsaturated hydrocarbon groups containing 2 to 7 carbon atoms such as,  
 for example, allyl, propenyl, butenyl, pentenyl, 1,1- dimethyl-propenyl, ethynyl and propargyl. The term alkanoyl, alone or in combination includes groups derived from branched-chain or straight-chain aliphatic carboxylic acids containing up to 6 carbon atoms such as, for example, acetyl, propionyl, butyryl and the like. The term aroyloxy includes groups derived from aromatic carboxylic acids containing 7-l5 carbon atoms such as, for example, benzoyloxy and naphthoyloxy, the aromatic nucleus being optionally substituted by lower alkyl. The term halogen includes fluorine, chlorine, bromine and iodine. Examples of 3-, 5-, 6- and 7-membered saturated heterocyclic rings are the aziridinyl, pyrrolidinyl, piperidinyl and azepinyl rings. Corresponding 5-, 6- or 7- membered saturated heterocyclic rings containing a further hetero atom are the thiazolidine, isoxazolidine, pyrazolidine, imidazolidine, oxazolidine, piperazinyl, morpholinyl, thiamorpholinyl, diazepinyl, thiazepinyl and oxazepinyl rings. The term acid addition salts includes known &#39;pharmaceutically acceptable acids, e.g., mineral acids such a hydrochloric, hydrobromic, sulfuric, etc. and organic acids such as acetic, succinic, maleic, benzenesulfonic, toluenesulfonic, methanesulfonic, etc.  
  Preferred compounds of formula I are those in which the variable nitro group is present in the 5-position, particularly those in which R represents lower alkyl, R represents hydrogen or lower alkyl and R represents hydrogen. Other preferred compounds of formula I are those in which R represents wherein R,, R and n have the significance given above.  
 Preferred are those compounds in which R and R together with the nitrogen atom to which they are attached represent a o-membered saturated heterocyclic ring and n stands for 2 and R and R are each hydrogen. As especially preferred 6-membered saturated heterocyclic ring is the morpholinyl ring.  
  A further preferred group of compounds represented by formula I are those in which R represents alkenyl and R represents hydrogen or lower alkyl. Especially preferred are those compounds in which R represents lower alkyl group, preferably methyl, and R represents hydrogen.  
 Of the compounds represented by formula I the following are preferred in this invention:  
 2-( 3,5-dinitro-2-thienyl )-isoxazolidine,  
 l-(3,S-dinitro-Z-thienyl)-aziridine,  
 4-( 3 ,5-dinitro-2-thienyl )-morpholine,  
 l-(3,5-dinitro-2-thienyl)-pyrrolidine,  
 3-(3,5-dinitro-2-thienyl)-thiazolidine, l-(3,5-dinitro-2-thienyl)-piperidine,  
 4-( 3 ,5-dinitro-2-thienyl l -piperazine-ethanol,  
 - l&#39;-(3,S-dinitro-Z-thienyl)-4-methylpiperazine, 2.-(3,5-dinitro-2-thienyl)-tetrahydro-2H-l,Z-oxazine. 2-chlor&#39;o-N-( 3,5-dinitro-2-thienyl)-acetamide, 2--bromo-N-( 3 ,5-dinitro-2-thienyl )-acetamide, 4-chloro-N-( 3,5-dinitro-2-thienyl )-butyramide,  
  3 2-chloro-N-(3,5-dinitro-2-thienyl)-N-methylacetamide, N-(2-chloroethyl)-3,5-dinitro-2-thiophenamine, 4-[ 2-[( 3 ,5-dinitro-2-thienyl )-amino]-et-hyl]- morpholine, N&#39;-(3,5-dinitro-2-thienyl)-N,N-  
  diethylethylenediamine, N 3,5-dinitro-2-thienyl)-N,N-diethyll ,3-  
  propanediamine, 2-[(3,5-dinitro-2-thienyl)-amino]-ethylmethylcarbamate, 4-[(3,5-dinitro-2-thienyl)-amino]-l-butanol, N-(2-methoxyethyl)-N-methyl-3,5-dinitro-2-&#39; thiophenamine, N-(3-ethoxypropyl)-3,5-dinitro-2-thiophenamine, N&#39;-(3,5-dinitro-2-thienyl)-N,N- dimethylethylenediamine. l-[(3,S-dinitro-Z-thienyl)-amino]-2-propanol, 2-[ 3 ,5-dinitro-2-thienyl )-amino]-isonicotinic ethyl ester, N-[2-(methylthio)-ethyl]-3,5-dinitro-2- thiophenamine, 2-[(3,5-dinitro-2-thienyl)-amino]-acetic acid ethyl ester, N-isobutyl-3,5-dinitro-2-thiophenamine, N-secbutyl-3,5-dinitro-Z-thiophenamine, N-allyl-3,5-dinitro-Z-thiophenamine, N-isopropyl-3,5-dinitro-2-thiophenamine, N-ethyl-3,5-dinitro-2-thiophenamine, N-butyl-3,5-dinitro-2-thiophenamine, N-(2-methoxyethyl)-3,5-dinitro-2-thiophenamine, 2-[(3,5-dinitro-thienyl)-amino]-ethanol, N,N-dimethyl-3,5-dinitro-2-thiophenamine, N-allyl-N-methyl-3,5-dinitro-2-thiophenamine, N-isobutyl-N-methyl-3,5-dinitro-2-thiophenamine and N-ethyl-N-methyl-3 ,S-dinitro-2-thiop henamine. The compounds of this invention are prepared by the following methods:  
 a. reacting a compound represented by the formula acid wherein Hal stands for chlorine, bromine or iodine and R has the significance given above, with an amine represented by the formula wherein R represents lower alkyl containing 2 to 7 carbon atoms, lower alkenyl, lower alkynyl, halo lower alkyl, hydroxy lower alkyl, lower aikoxy lower alkyl or lower alkylthio lower alkyl or R and R together with the nitrogen atom to which they are attached represent a 3-, 5-, 6- or 7-membered saturated heterocyclic ring which, in the case of a 5-, 6- or 7-membered ring, may contain a further nitrogen atom or an oxygen or sulphur atom and which may be substituted by lower alkyl or hydroxy lower alkyl,  
 or a pharmaceutically acceptable acid addition salt thereof.  
  This reaction is carried out in an inert solvent such as, for example, an aqueous lower alkanol, perferably methanol or ethanol, dimethylformamide, a chlorinated hydrocarbon, preferably methylene chloride or chloroform, or dimethyl sulphoxide. The reaction is advantageously carried out at a temperature between 0C. and the boiling point of the reaction mixture. An especially preferred temperature lies at between 15C. and 40C. The pressure is not critical; the reaction is preferably carried out in an open vessel. If the amine represented by formula III is used in the form of a salt such as, for example, a hydrohalide, a weak base such as, for example, potassium carbonate is expediently added to the reaction mixture. The working up of the reaction mixture is carried out in the usual manner by removal of the solvent and recrystallization of the residue.  
 b. nitrating a compound represented by the formula wherein R,, R and R have the significance given above and wherein R is present either in the 4- or in the 5-position and Y represents hydrogen or nitro.  
  For this reaction it is immaterial whether Y represents hydrogen or nitro in a compound represented by formula IV. In either case, a compound represented by formula IV is expediently first dissolved in concentrated sulphuric acid at a low temperature, preferably O-20C., and then pro-cooled, for example, at 0-20C., concentrated sulphuric acid and concentrated nitric acid are added with cooling. The procedure by which the nitric acid is introduced into the mixture is, however, not critical. For example, sodium nitrate can also be added to sulphuric acid. It is important only that the nitric acid is present in approximately a stoichiometric amount or in a slight excess and the temperature is kept sufficiently low and remains controllable. The latter is achieved in a simple manner by carefully adding the nitrating agent dropwise. After the nitrating agent has been added, the mixture is poured on to ice and extracted with, for example, ethyl acetate. The ethyl acetate extracts are washed several times with water, dried and evaporated. The residue is then purified by conventional means known to the art. c. reacting a compound represented by the formula wherein R and R have the significance given above,  
 with a lower alkylating, lower alkenylating, lower alkynylating or lower alkanoylating agent, the alkyl group in the lower alkylating agent being substituted if desired by halogen, hydroxy, lower alkoxy. lower alkanoyloxy, lower aroyloxy, pyridylcarbonyloxy, lower alkylaminocarbonyloxy or lower alkylthio and containing, in the case of a monoalkylation with an unsubstituted alkylating agent, from 2 to 7 carbon atoms, and the alkyl group in the lower alkanoylating agent being substituted if desired by halogen.  
  In this procedure a compound represented by formula V is dissolved in an organic solvent, e.g., a lower alkanol, preferably methanol or ethanol, an ether such as dioxane, or a di-lower alkyl ketone such as acetone or dimethylformamide, and the resulting mixture is treated with an alkali metal carbonate or alkaline earth metal carbonate, preferably sodium carbonate or potassium carbonate. The mixture thus obtained is treated with the alkylating, alkenylating or alkynylating agent. Conventional alkylating, alkenylating or alkynylating agents such as, for example. halides with the exception of fluorides, alkylsulphonyloxy derivatives, preferably mesyloxy derivatives, or arylsulphonyloxy derivatives, preferably tosyloxy derivatives can be used. The reaction is advantageously carried out at a temperature between 0C. and the boiling point of the mixture, preferably at the reflux temperature. If it is desired to manufacture compounds represented by formula l in which R represents. for example, halo lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl or lower alkylthio lower alkyl and/or R represents lower alkoxy lower alkyl or hydroxy lower alkyl, the appro-- priate alkylating agents which are substituted in the lower alkyl group by halogen, hydroxy. alkoxy or alkylthio are used. The pressure is not critical; the reaction can be carried out in an open vessel.  
 d. reacting a compound represented by the formula (m mt wherein R R n and Hal have the significance given above,  
  with an amine represented by formula III.  
  This reaction is carried out according to methods known per se, expediently in the presence of an excess of an amine represented by formula Ill which can thus serve as the solvent. The reaction can, however, also be carried out in an inert organic solvent such as a hydrocarbon e.g., benzene or toluene, a chlorinated hydrocarbon e.g., methylene chloride, an ether e.g., diethyl ether and the like. The excess amine represented by formula [II can also serve as an acid-binding agent. However, there can also be used for this purpose other bases such as potassium carbonate, sodium carbonate and the like. The temperature and pressure are not critical. but the reaction is preferably carried out at a temperature between about 0C. and the reflux tempera- 02H 2 VII f wherein R, has the significance given above and R represents lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy lower alkyl, lower alkylthio lower alkyl or halo lower alkyl, the alkyl group in the alkanoylating agent being substituted if desired by halogen.  
 f. reacting a compound represented by the formula VIII wherein R;, has the significance given above and R represents lower alkylcarbonyl or halo lower alkylcarbonyl, with a lower alkylating, lower alkenylating or lower alkynylating agent, the alkyl group in the lower alkylating agent being substituted if desired by halogen, hydroxy, lower alkoxy, lower alkanoyloxy, lower aroyloxy, pyridylcarbonyloxy, lower alkylaminocarbonyloxy or lower alkylthio.  
  These processes of alkanoylation of a compound represented by formula Vll or alkylation, alkenylation of a compound represented by formula Vlll are carried out in the manner and with the reagents detailed above for embodiment c) of the process.  
  g. treating a&#39; compound represented by formula I in which R and R together with the nitrogen atom to which they are attached represent a 3-membered saturated hetercyclic ring with a lower alkanol in the presence of an acid. Preferably a strong organic or mineral acid is used, e.g. p-toluolsulfonic acid, trifluoroacetic acid, sulfuric acid, nitric acid etc. Sulfuric acid is prefered.  
 h. reacting a compound represented by the formula wherein R R and n have the significance given above 1 with a lower alkanoylating, lower aroylating or pyridoylating agent or with a lower alkyl isocyanate. I The reaction is carried out using a suitable functiona derivative of a corresponding carboxylic acid, for example, a lower alkanecarboxylic acid such as actic acid or a lower arylcarboxylic acid such as benzoic acid. Amongst the suitable reactive functional derivatives of such carboxylic acids for the acylation of compounds represented by formula V or lX there may be mentioned, for example, the anhydrides such as acetic anhydride, chloroacetic acid anhydride and the like, acid halides such as acetyl chloride and benzoyl chloride, imidazolides such as propionic acid imidazolide and chloroacetic acid imidazolide as well as other reactive derivatives suitable as acylating agents.  
  The conditions used for the foregoing acylation are not critical and can be readily selected according to the carboxylic acid derivative chosen as the alkanoylating agent. The acylation can be carried out, for example, at room temperature or at a temperature above or below room temperature depending on the chosen reagent. Moreover, the acylation is expediently carried out in a conventional inert organic solvent such as a hydrocarbon e.g., benzene, toluene and the like, a chlorinated hydrocarbon e.g., methylene chloride and the like, an ether e.g., tetrahydrofuran and the like, dimethylformamide, pyridine and the like.  
 The acylation can also be advantageously carried out in the absenceof an inert solvent, in which case the acylating agent serves as the solvent. Further, it is expedient to add small amounts of dimethylformamide to the acylation.  
  If a compound represented by formula [X is reacted with a lower alkyl isocyanate there is obtained a compound represented by formula 1 in which R, represents lower alkylaminocarbonyloxy lower alkyl. This reaction is expediently carried out in an inert organic solvent such as, for example, ether, petroleum ether, dioxane, tetrahydrofuran, etc. The reaction can be carried out at a temperature above or below room temperature. A preferred temperature lies between C. and 40C. The-reaction is expediently. carried out in the presence of small amounts of a base, Organic bases such as pyridine, quinoline or triethylamine are preferred. I  
  i. Converting a basic compound represented by formula l into a pharmaceutically acceptable acid addition salt.  
  Certain of the compounds represented by formula I which bear at least two nitrogen atoms in the side chain, e.g. N&#39;-(3,5-Dinitro-2-thienyl)-N,N-diethylethylendiamine are basic and the manufacture of their acid addition salts, especially those which are pharmaceutically acceptable, also forms part of the present invention. These salts can be manufactured from the corresponding bases according to generally known methods by reaction with suitable inorganic or organic acids. Examples of organic or inorganic acids which can be used for the manufacture of pharmaceutically acceptable acid addition salts are hydrochloric acid, hydrobromic acid, sulphuric acid, acetic acid. succinic acid, maleic acid, methanesulphonic&#39;acid, benzenesulphonic acid, p-toluenesulphonic acid, etc-The nonpharmaceutically acceptable acid addition salts of the Hal &#39;wherein Hal and R have the significance given above,  
 with a nitrating agent of the type previously described in connection with embodiment b) of the process.  
  Certain of the starting materials represented by formulalV are also novel. The compounds represented by formula IV in which Y represents hydrogen can be prepared by reducing the nitro group in a compound represented hy the formula wherein R, has the significance given in formula IV, to the amino group and introducing the substituents R, and R as described above. The reduction is carried out using concentrated-aqueous hydrochloric acid and fine tin powder at 40-45C. as described in Ann. 403, 17 (1914). An amine thus obtained can be mononitrated after protection of the amino group with, for example, an acetyl group. After hydrolysis of the protecting group and introduction of the substituents R, and R a compound represented by formula IV in which Y represents a nitro group is obtained. For the mononitration, a protected amine is dissolved in acetic anhydride and the mixture is mixed with a solution of glacial acetic acid and nitric acid (65400 percent) at a temperature between 30C. and +40C. The working up is carried out by conventional means. The introduction of the substituents R, and R is carried out in the manner described above.  
  The reduction of a compound represented by formula X yields a compound represented by the formula S NH:  
 wherein R, has the significance given in formula IV,  
 and such a compound, after protection of the amino group and nitration in the manner described above as well as subsequent removal of the protecting group. yields a compound represented by the formula wherein R has the significance given above and Z rcpresents-nitro.  
  A starting material represented by formula V is obtained from a compound represented by formula-XII by dinitration as described above. The compounds represented by formulae VI, VII and VIII are obtained by alkylation or alkanoylation&#39; of compounds represented by formula \l aspreviously described herein.  
  The compoundsrepresented by formula I and the pharmaceutically acceptable acid addition salts of those compounds which are basic possess protozoacidal, bactericidal, anthelmintic and schistosomicidal activity. They can be used, for example, for the therapy of bilharzia. The schistosomicidal activity predominates in the 3.5-dinitro-thiophene compounds while, in  
 the 3,4-dinitro-thiophene compounds, the bactericidal activity predominates. The following test demonstrates the schistosomicidal activity of compounds represented by formula I: I A  
  Golden hamsters are infected subcutaneously with 60 cercaria of Schistosoma mansoni. Approximately 42 days after the infestion, the hamsters are treated on 5 successive days with the test compounds. 5-10 hamsters are used per compound and dosage (mg/kg). untreated hamsters are used as controls. The dissection is carried out 6 days or 2-3 weeks after the termination of the treatment. Worm pairs in the mesenteric veins, portal vein and liver are dissected out and counted. The percentage distribution of the worm pairs in the mesen teric veins, portal vein and liver is calculated and the condition of the worms (living, dead) registered. The action of the compound is shown in an increased proportion of worms in the vessels of the liver and in the appearance of dead worms.  
  For evaluation, the percentage proportion of living and dead worm pairs in the vessels of the liver is compared not only in the infected treated hamsters but also in the infected but untreated control hamsters. The calculation of the SD (Shift Dose 90 percent, i.e., the dose which dispels 90 percent of the worm pairs into the liver in a group of treatedv hamsters) and the VD (vermicidal Dose 90 percent, i.e., the dose which kills 90 percent of the worm pairs) is carried out according to the Probit method.  
 Representative test results are compiled in the fol- QxIII The compounds represented by formula I and pharmaceutically acceptable acid addition salts of those compounds which are basic can be used as medicaments in the form of pharmaceutical preparations which contain them in association with a compatible pharmaceutical carrier material. This carrier material can be a conventional organic or inorganic carrier material suitable for enteral or parenteral administration such as gelatin, lactose, starch, gum arabic, magnesium stearate, talc, vegetable oils, polyalkyleneglycols, petroleum jelly and the like. The pharmaceutical preparations can be made up in solid form (e.g., as tablets or dragees) or in liquid form (e.g., as solutions, suspensions or emulsions). They can contain adjuvants such as preservatives, stabilizers, wetting agents.emulsifiers, salts for the&#39;variation of the osmotic pressure or buffers. They may also contain other therapeutically active materials.  
  Expedient pharmaceutical dosage forms contain 100 500 mg, preferably about 250 mg., of active ingredient.  
  The dosage is chosen according to the individual requirements. For example, the compounds represented by formula I can be administered in dosages of about 10 mg./kg. to about 50 mg./kg. per day p.o., preferably 25 mg./kg. per day p.o. These amounts can be administered in a single dosage or in several subdivided dosages according to the requirements of the patient and instruction of the attending physician. Expediently, the dose is administered in relation to the condition of the patient on several successive days, preferably on 5 to 8 successive days.  
 EXAMPLE 1 10 g. of 2-chloro-3,S-dinitrothiophene are treated in 200 ml. of methanol with 5.5 ml. of ethyleneimine and stirred at room temperature. The reaction product precipitates and is filtered off under a vacuum. The precipitated product is washed with a small amount of methanol, methanol/petroleum ether and petroleum ether (low boiling) and purified on a short column (150 g. of silica gel; eluant: methylene chloride). There is obtained l-( 3,5-dinitro-2-thienyl)-aziridine of melting point 140C. (from methylene chloride/petroleum ether).  
 EXAMPLE 2 10 g. of 2-chloro-3,5-dinitrothiophene are treated in 100 ml. of methanol with 9 g. of morpholine and stirred at room temperature. The reaction product is isolated by distilling off the methanol. The resulting product is purified directly on a Kieselgel column. There is obtained 4-(3,5-dinitro-2thienyl)-morpholine from methylene chloride/petroleum ether as a pure crystallowing Table: line product of melting point l33-l36C.  
 TABLE 5D,, VD Compound mg./kg. mg./kg.  
 2-Chloro N-(3,5 dinitro-2-thicnyl)-acctamide 215 2l5 N-Meth&#39;yl 3,5 dinitro2-thiophcnaminc Y 155 I -(2.-Chloroethyl)-3 ,5 dinitro-2-thiophenaminc&#39; I65 I ,N-Dimcthyl-3.5-dinitro-2-thiophcnaminc I80 I &#39;-(3,5-Din&#39;itro-2-thicnyl l-thiazolidinc l 50 l 50 3,S-Dinitro-Z-thicnyl)-N,N-dimcthylethylencdiamine. 2 I0 215 Z-Hydroxyethyl )-3,5-dinitro-2-thiophcnaminc 200 -(2 McthoxyethyI)-3,5-dinitrwZ-thiophcnamint: 205 210 l-(3,5-Dinitro-2-thicnyl)-piperidinc I 205 240 N-MethylN-allyl-3,S-dinitro2-thiophcnamine 220 EXAMPLE 3 10 g. of 2-chloro-3,S-dinitrothiophene are treated in 100 ml. of methanol with 7 g. of pyrrolidine and stirred at room temperature. Thereafter the methanol is distilled off. The resulting product, l-(3.5-dinitro-2-thienyl)-pyrrolidine, which is crystallized from methylene chloride/petroleum ether, melts at l20-l25C.  
 EXAMPLE 4 500 mg. of 2-chloro-N-(3-benzoyl-2-thienyl)- acetamide are introduced into 2.5 ml. of concentrated sulphuric acid at lOC. and stirred. A solution of 0.3 ml. of concentrated nitric acid (d=l .42) and 0.5 ml. of concentrated sulphuric acid is added dropwise and the mixture is stirred at lOC. for 0.5 hour.  
  The mixture is poured on to ice in 10 percent sodium bicarbonate solution and the aqueous solution extracted several times with methylene chloride. The combined methylene chloride solutions are dried over magnesium sulphate, filtered and concentrated. The mixture is purified on a Kieselgel column and crystallized from ethanol. There is obtained 2-chloro-N-(3,5- dinitro-Z-thienyl)-acetamide of melting point l44-l50C.  
 EXAMPLE 5 7.5 g. of chloroacetic anhydride and 5 ml. of ether are added to 6.4 g. of 2-amino-thiophene chlorohydrate-tin chloride in 18 ml. of water. 8 g. of sodium hydroxide in 8 ml. of water are then added dropwise over a period of 10-15 minutes with ice-cooling and stirring. The precipitated product is filtered off under a vacuum and partly dissolved in methylene chloride which had been dried over magnesium sulphate.  
  After filtration and concentration of the methylene chloride solution, the mixture is purified on a Kieselgel column (eluant: methylene chloride) to obtain 2- chloro-N2-thienyl-acetamide of melting point 136C. (from ether/petroleum ether).  
 EXAMPLE 6 A. 200 g. of 2-amino-thiophene chlorohydrate-tin chloride are stirred with 680 g. of potassium carbonate, 200 ml. of chloroacetyl chloride and 2 liters of ethyl acetate while cooling with ice/sodium chloride at 0-l0C. There are then added dropwise L500 ml. of water. The ethyl acetate is then separated and the aqueous solution washed several times with ethyl acetate. The combined ethyl acetate solutions are then dried over magnesium sulphate, filtered and concentrated. The residue is partly dissolved in methylene chloride and the insoluble material boiled several times with methylene chloride and decanted off. The combined methylene chloride solutions are evaporated to obtain crude 2-chloro-N2-thienyl-acetamide.  
  B. 90 g. of the crude 2-chloro-N2-thienyl-acetamide are dissolved at lOC. in 250 ml. of concentrated sulphuric acid and a precooled (lOC.) nitrating solution (100 ml. of concentrated sulphuric acid and 72 ml. of concentrated nitric acid: 65 percent, d =l.4) is slowly added dropwise with stirring and with control of the temperature at lOC. Immediately after the completion of the addition of the nitrating agent, the mixture is poured on to ice and extracted several times with ethyl acetate. The combined ethyl acetate solutions are EXAMPLE 7 Following the procedures of Example 6A and B, 2- bromo-N-(3,5-dinitro-2-thienyl)-acetamide of melting point l38139C. (from methylene chloride/petroleum ether) is obtained by reacting 2-aminothiophene chlorohydrate-tin chloride and bromoacetyl bromide.  
 EXAMPLE 8 Following the procedures of Example 6A, 4-chloro- N-Z-thienyl-butyramide of melting point 9496C. (from ether/petroleum ether) is obtained by reacting 2-amino-thiophene chlorohydrate-tin chloride and 3- chloro-butyric acid chloride.  
 EXAMPLE 9 Following the procedures of Example 63, 4-chloro- N-(3,5-dinitro-2-thienyl)-butyramide of melting point -92C. (from methylene chloride/petroleum ether) is obtained by nitration of 4-chloro-N-2- thienylbutyramide.  
 EXAMPLE l0 12 g. of N-methyl-3,5-dinitro-Z-thiophenamine are heated overnight under reflux in 30 ml. of chloroacetyl chloride with the addition of a few drops of dimethylformamide. The chloroacetyl chloride is then distilled off on a rotary evaporator. The residue is then dissolved in methylene chloride and washed with 10 percent bicarbonate solution.  
  The methylene chloride solution is then dried over magnesium sulphate, filtered and concentrated. The residue is purified on a Kieselgel column (300 g. of Kieselgel; eluant: methylene chloride) to obtain 2-chloro- N-(3,5-dinitro-2-thienyl)-N-methylacetamide of melting point 9496C. (from ether/hexane).  
 EXAMPLE l1 5 g. of 2-chloro-3,5-dinitrothiophene are suspended in 50 ml. of absolute methanol and treated with 5 g. of chloroethylamine hydrochloride and 5 g. of potassium carbonate. The mixture is warmed on a steam bath for 5 minutes, the methanol is evaporated and the residue extracted with methylene chloride/water.  
  The methylene chloride solution is then dried over magnesium sulphate, filtered and concentrated. The residue is purified on a Kieselgel column (eluant: meth- &#39;ylene chloride). The product. N-(2-chloroethyl)-3.5- dinitro-2-thiophenamine of melting point 137C, is crystallized from ethanol.  
 EXAMPLE 12 EXAMPLE 13 Following the procedures of Example 2, N-isobutyl- 3,5-dinitro-2-thiophenamine which is recrystallized from methylene chloride/petroleum ether and has a melting point of 80-82C. is obtained by reacting 10 g. of 2-chloro-3,5-dinitrothiophene and 8 g. of isobutylamine and using 120 ml. of methanol as solvent.  
 EXAMPLE 14 Following the procedures of Example 13, N-secbutyl- 3,5-dinitro-2-thiophenamine of melting point 8587C. (from methylene chloride/petroleum ether) is obtained by reacting 2-chloro-3,S-dinitrothiophene and Z-aminobutane.  
 EXAMPLE 15 Following the procedures of Example 1 l, N-allyl-3,5- dinitro-2-thiophenamine of melting point 8788C. (from methylene chloride/petroleum ether) is obtained by reacting 10 g. of 2-chloro-3,5-dinitrothiophene and 9 ml. of allylamine using 100 ml. of methanol as solvent.  
 EXAMPLE 16 Following the procedures of Example ll, N- isopropyl-3,5-dinitro-2-thiophenamine of melting point l40-l42C. (from methylene chloride/petroleum ether) is obtained by reacting l g. of 2-chloro-3,S-dinitrothiophene and 6.5 g. of isopropylamine using 120 ml. of methanol as solvent.  
 EXAMPLE 17 Following the procedures of Example 1 1, there is obtained N-ethyl-3,5-dinitro-2-thiophenamine of melting point l4l-l43C. (from methylene chloride/petroleum ether) is obtained by reacting 10 g. of 2-chloro-3,S-dinitrothiophene and g. of ethylamine dissolved in 20 ml. of methanol and using as the solvent 100 ml. methanol.  
 EXAMPLE 18 Following the procedures of Example ll, N-butyl- 3,5-dinitro-2-thiophenamine of melting point 6064C. (from ethanol) is obtained by reacting g. of 2-chloro-3,S-dinitrothiophene and 8 g. of nbutylamine using 100 ml. of methanol as solvent.  
 EXAMPLE 19 l g. of l-(3,5-dinitro-2-thienyl)-aziridine is suspended in ml. of methanol containing 3 drops of concentrated sulphuric acid and heated on a steam bath for 5 minutes under anhydrous conditions. After standing for 15 minutes at room temperature, the mixture is concentrated and the residue extracted with methylene chloride/l0 percent bicarbonate solution.  
  vThe methylene chloride solution is then dried over magnesium sulphate, filtered and concentrated. The residue is purified on Kieselgel column to obtain N-( 2- methoxyethyl)-3,5-dinitro-2-thiophenamine of melting point l40-l4lC. (from methylene chloride/petroleum ether).  
 EXAMPLE 2O 20 g. of l-(3,5-dinitro-2-thienyl) aziridine are heated on a steam bath for 15 minutes in 400 ml. of water, 200 ml. of dioxane and 200 ml. of 2-N sulphuric acid. The resulting insoluble material is filtered off and the filtrate concentrated on a rotary evaporator to ca 200 ml. The resulting solution is then extracted three times with ethyl acetate. The combined ethyl acetate solutions are dried over magnesium sulphate, filtered and concentrated. The resulting residue is purified on a Kieselgel column (eluant: methylene chloride; methylene chloride/ethyl acetate 20%). The product, 2-[(3,5-dinitrothienyl)-amino]-ethanol of melting point l27l 30C., is then crystallized from ethyl acetate/petroleum ether.  
 EXAMPLE 21 Following the procedures of Example 1 l, N,N- dimethyl-3,5-dinitro-2-thiophenamine of melting point 155C. (recrystallized from ethanol) is obtained by reacting 2-chloro-3.5-dinitrothiophene and 5 g. of dimethylamine using 100 ml. of methanol as solvent.  
 EXAMPLE 22 6.4 g. of N-allyl3,5-dinitro-2-thiophenamine are stirred overnight at room temperature in 60 ml. of absolute acetone with 4.5 g. of potassium carbonate (anhydrous, finely powdered) and 4 ml. of dimethyl suphate. The resulting precipitated inorganic material is then filtered off and washed with acetone. The combined acetone solutions are concentrated and purified on a Kieselgel column to obtain N-allyl-N-methyl-3.5- dinitro-2-thiophenamine of melting point 7778C. (from methylene chloride/petroleum ether).  
 EXAMPLE 23 Following the procedures of Example 22, N-isobutyl- N-methyl-3,5-dinitro-2-thiophenamine of melting point 1 l6-l l8C. (from methylene chloride/petroleum ether) is obtained by the reaction of 5.2 g. of N- isobutyl-3,5-dinitro-2-thiophenamine, 5 g. of potassium carbonate and 3.6 g. of dimethyl sulphate using 80 ml. of acetone as solvent.  
 EXAMPLE 24 Following the procedures of Example 22, N-ethyl-N- methyl-3,5-dinitro-2-thiophenamine of melting point 6566C. (from methylene chloride/petroleum ether) is obtained by reacting 7 g. of N-ethyl-3,5-dinitro-2- thiophenamine, 13 g. of potassium carbonate and 7.5 ml. of dimethyl sulphate using ml. of acetone as solvent.  
 EXAMPLE 25 Following the procedures of Example 2, l-( 3,5- dinitro-2-thienyl)-piperidine is obtained by reacting 2 g. of 2-chloro-3,S-dinitrothiophene and 17 g. of piperidine using 40 ml. of methanol as solvent. The product. crystallized from ether/petroleum ether, melts at 88-90C.  
 EXAMPLE 27 Following the procedures of Example 1, N-(3- ethoxypropyl)-3.5-dinitro-2-thiophenamine is obtained by reacting 8 g. of 2-chloro-3,5-dinitrothiophene and 8 g. of ethoxy-propylamine, using 120 ml. of ethanol as solvent. The product is crystallized from methylene chloride/petroleum ether and melts at 86C.  
 EXAMPLE 28 Following the procedures of Example 1, N&#39;-(3,5- dinitro-Z-thienyl)-N,N-dimethylethylenediamine is obtained by reacting 8 g. of 2-&#39;chloro-3.S-dinitrothibphene and 9 ml. of dimethylaminoethylamine, using 100 ml. of ethanol as solvent. The product is crystallized from ethanol and melts at 117C.  
 EXAMPLE 29 Following the procedures of Example 2, 1-[(3,5- dinitro-2-thienyl)-amino]-2-propanol is obtained by reacting 8 g of 2-chloro-3,5-dinitrothiophene and 6 g.  
 of l amino-2-propanol, utilizing as solvent 100 m1. of ethanol. The product is crystallized from methylene chloride/petroleum ether and melts at 1 12C.  
 EXAMPLE 30 Following the procedures of Example 1, 4-(3,5- dinitr0-2-thienyl)-l-piperazine-ethanol, is obtained &#34;by reacting 8 g. of 2-chloro-3,5-dinitrothiophene and 10.4 g. of hydroxyethylpiperazine, using 120 ml. of ethanol as solvent. The product is crystallized from methylene chloride/petroleum ether and melts at 120C.  
 EXAMPLE 31 Following the procedures of Example 1, l- (3.5--&#34;  
 dinitro-2-thienyl)-4-methylpiperazine is obtained by reacting 8 g. of 2-chloro-3,S-dinitrothiophene and 8 g. of N-methylpiperazine, using 120 ml. of ethanol as solvent. This product is crystallized from methylene chloride/petroleum ether and melts at 125C.  
 EXAMPLE 32 1.4 g. of 2-[(3.5-dinitro-2-thienyl) amino]-ethanol are treated in 30 ml. of methylene chloride with 1.2 g. of isonicotinic acid chloride. The resulting product is heated at reflux for 0.5 hour, then poured on to 10% ice/sodium bicarbonate solution, extracted with ether and dried over sodium sulphate. The filtered solution is concentrated and purifiedover a short column (30 g. of silica; eluant: methylene chloride/petroleum ether). The aminol-isonicotinic acid ethylester which is obtained by crystallizing from methanol/methylene chloride melts at 185l88C.  
 product, I 2-[(3.5-dinitro-2-thienyl)- EXAMPLE 33 Following the procedures of Example 11, 2-(3,5- dinitro-2-thienyl)-isoxazolidine is obtained by reacting 8 g. of 2-chloro-3,S-dinitrothiophene, 5 g. of potassium carbonate and 5 g. of isoxazolidine hydrochloride, using ml of methanol as solvent. The product is crystallized from methylene chloride/petroleum ether and melts at C.  
 EXAMPLE 34 Following the procedures of Example 20, N-(2- methylthioethyl)-3,5-dinitro-2 thiophenamine, is obtained by reacting 20 g. of l-(3,5-dinitro-2-thienyl)- aziridine, 100 ml. of dioxane solvent saturated with methyl mercaptan, the dropwise addition of a total of 3-4 ml. of concentrated sulphuric acid and further introduction of methyl mercaptan. The product is crystallized from methylene chloride/petroleum ether and melts at 1 14C.  
 EXAMPLE 35 Following the procedures of Example 2, N-(Z- methylthioethyl)-3,5-dinitrQ-Z-thiophenamine is obtained by reacting 20 g. of 2-chloro-3,S-dinitrothiophene and 2-methylthioethylamine (prepared from 24 g. of 2-chloroethylamine chlorohydrate, 10 g. of methyl mercaptan and 25 g. of potassium hydroxide), using 200 ml. ethanol as solvent. The product is crystallized from methylene chloride/petroleum ether and melts at 114C.  
 EXAMPLE 36 Following the procedures of Example 13, 2-[(3,5- dinitro-Z-thienyl)-amino]-acetic acid ethyl ester. is obtaitned by reacting 2 g. of 2-[(3,5-dinitro-2-thienyl)- amino]-ethanol in 30 ml. of methylene chloride with 1 g. of acetyl chloride and 1 g. of piperidine. The product is crystallized from methylene chloride/petroleum ether and melts at C.  
 EXAMPLE 37 Following the procedures of Example 14, 2-(3.5- dinitro-Z-thienyl)-tetrahydro-2H-l,2-oxazine. is obtained by reacting 20 g. of 2-chloro-3,S-dinitrothiophene, 17 g. of isoxazine chlorohydrate and 15 g. of potassium carbonate, using 200 ml. of methanol as solvent. The product is crystallized from methylene chloride/petroleum ether and melts at 8688C.  
 EXAMPLE 38 Following the procedures of Example 2, N-(3,5- dinitro-2-thienyl)-N,N-diethylethylenediamine, is obtained by reacting 8 g. of 2-chloro-3,S-dinitrothiophene and 8.5 g. of diethylaminoethylamine, using 150 ml. of ethanol as solvent. The product is crystallized from methylene chloride/petroleum ether and melts at 75-76C.  
 EXAMPLE 39 Following the procedures of Example 1, N&#39;-(3,5- dinitro-2-thienyl)-N,N-diethyl-l.3-propanediamine is obtained by reaction of 10 g. of 2-ch10ro-3,5-dinitrothiophene and&#39;l3 g. of 3-diethylamino-l-propylamine. using 100 ml. of ethanol as solvent. The product is crystallized from ethyl acetate/petroleum ether and melts at 116C.  
 EXAMPLE 40 2.8 g. of 2-[(3, -dinitro-2-thienyl)-amino]-ethanol, 1 ml. of methyl i&#39;so&#39;cy anate and 4 drops of triethylamine in 30 ml. of dio&#39;xane are mixed together and left to stand for 6 days at room temperature. The mixture is then concentrated and chromatographed on a Kieselgel column [eluant: methylene chloride/ethyl acetate (:1 The resulting 2-[(3,5-dinitro-2-thienyl)- aminol-ethylmethylcarbamate is crystallized from ethanol/methylene chloride and melts at l70l74C.  
 EXAMPLE 41 Following the procedures of Example 2, 4-[(3,5- dinitro-2-thienyl)-amino]-l-butanol is obtained by the reactionof 10 g. of 2- chloro-3,S-dinitrothiophene and 9 g. of 4-aminobutano l-l. using 120 ml. of ethanol as solvent. The product is recrystallized from ethanol/- methylene chloride/petroleum ether and melts at 90C.  
 EXAMPLE 42 Following the procedures of Example 2, 3-(3,5- dinitro-Z-thienyl)-thiazolidine is obtained by reacting 5 g. of 2-chloro-3,S-dinitrothiophene and 4.5 g. of thiazolidine, using 70 ml. of ethanol as solvent. The product is crystallized from methylene chloride/petroleum ether and melts at 126-128C.  
 EXAMPLE 43 g. of 2.5-dibromo-3,4-dinitrothiophene are treated in 200 ml. of methanol with 5.5 g. of dimethylamine in 55 ml. of methanol. The resulting mixture is stirred at room temperature for 2 hours, the methanol evaporated and the residue extracted with methylene chloride/water. The methylene chloride solution is then dried over magnesium sulphate, filtered and concentrated. The resulting residue is purified on a Kieselgel column (eluant: methylene chloride). 5-bromo-N,N- dimethyl-3,4-dinitro-2-thiophenamine is crystallized from methylene chloride/petroleum ether and melts at 139-l4lC.  
 EXAMPLE 44 8 g. of 2-bromo-4methyl-3,S-dinitrothiophene are treated in 100 ml. of ethanol with 4 g. of ethylene imine in 20 ml. of ethanol. The resulting mixture is stirred at room temperature. There is first obtained a clear solution and then the reaction product crystallizes out. After cooling with ice. the product is filtered off and crystallized from methylene chloride/petroleum ether to yield 1 -(4-methyl-3.5-dinitro-2-thienyl)-aziridine having a melting point of 161C.  
 EXAMPLE 45 Following the procedures of Example 11, 4-(3,5- dinitro-Z-thienyl )-tetrahyro-2H- l ,4-thiazine which melts at l58l64C. after recrystallization from methylene chloride/petroleum ether is obtained, after stirring a mixture of 20 g. of 2-chloro-3,S-dinitrothiophene, 300 ml. of methanol, 15 g. of thiomorpholine hydrochloride and 16 g. of potassium carbonate for a period of 2 hours.  
 EXAMPLE 46 5 g. of 2-[(3.5-dinitro-2-thienyl)-amino]-ethanol are boiled for 5 hours with 80 ml. of formic acid. The formic acid is then distilled off on a rotary evaporator. The  
 resulting residue is dissolved in methylene chloride and washed with 10 percent bicarbonate solution. The methylene chloride solution is dried over magnesium sulphate, filtered and concentrated. The residue is purified on a Kieselgel column (eluant: methylene chloride) to yield 2-[(3,5-dinitro-2-thienyl)-amino]-ethyl formate which is crystallized from methanol/petroleum ether and melts at 122C.  
 EXAMPLE 47,  
  10 g. of N-methyl-3,5-dinitro-2-thiophenamine are heated to reflux for 5 hours in 35 ml. of propargyl bromide with the addition of 5 m1. of dimethylformamide and 10 g. of potassium carbonate. The propargyl bromide is distilled off and the residue dissolved in methylene chloride and washed with water. The resulting methylene chloride solution is dried over magnesium sulphate, filtered and concentrated. The residue is purified on a Kieselgel column (eluant: methylene chloride) to yield N-methyl-3,5-dinitro-4-(2-propynyl)-2- thiophenamine which is recyrstallized from methylene chloride/petroleum ether and melts at l17l 19C.  
 EXAMPLE 48 Following the procedures of Example 6B, 2-chloro- N-(3,5-dinitro-2-thienyl)-acetamide which, after recrystallization from methylene chloride/petroleum ether, melts at l48-15 1C. is obtained by nitrating 2- chloro-N-(5-nitro-2-thienyl)-acetamide.  
 EXAMPLE 49 Following the procedures of Example 1 l, 4-[ 3-[(3,5- dinitro-2-thienyl)-amino]-propyl]-morpholine which melts at 125C. after recrystallization from methylene chloride/petroleum ether is obtained after stirring a mixture of 7 g. of 2-chloro-3,S-dinitrothiophene, 60 ml. of methanol, 10 g. of 3-aminopropylmorpholine dihydrochloride and 12 g. of potassium carbonate.  
 EXAMPLE 50 Following the procedures of Example 1, N-(3- methoxypropyl)-3,5-dinitro-2-thiophenamine which melts at 87C. after recrystallization from methylene chloride/petroleum ether is obtained by reacting 8 g. of 2-chloro-3.S-dinitrothiophene and 8 g. of methoxypropylamine, using ml. of ethanol as solvent.  
 EXAMPLE 51 EXAMPLE 52 Following the procedures of Example 43, S-bromo- N-( 2-methoxyethyl )-3,4-dinitro-2-thiophenamine which melts at 143C. after recrystallization from de/petroleum methylene chloride/petroleum ether is obtained by reacting g. of 2,5-dibromo-3,4-dinitrothiophene and 760 mg. of methoxyethylamine. using 80 ml. of ethanol as solvent.  
 EXAMPLE 53 Following the procedures of Example 2, 3-[(3.5- dinitro-Z-thienyl)-amino]-l-propanol which melts at 114C. after recrystallization from methylene chloriether is obtained by reacting 2-chloro-3,S-dinitrothiophene and 6 g. of 3-amino-lpropanol, using 80 ml. of ethanol as solvent.  
 EXAMPLE 54 using 200 ml. ethanol as solvent.  
  The following Examples illustrate typical pharmaceutical preparations containing the compounds represented by formula l:  
 EXAMPLE A Capsules of the following composition are produced:  
 Compound of formula I Lactose Maize starch Talc 250.0 mg. l55.0 mg. 30.0 mg. l5.0 E.  
  The compound of formula I is mixed homogeneously with the lactose and maize starch, passed through a screen-machine and, after intermixing of the tale, filled into gelatin capsules No. 4.  
 Filled capsule weight Content of compound of formula I 450 mg. 250 mg.  
 EXAMPLE B Tablets of the following composition are produced:  
 Compound of formula I Lactose Maize starch Ethyl cellulose Talc Magnesium stearatc 250.0 mg. l00.0 mg. 85.0 mg. 10.0 mg. 4.5 mg. 0.5 mg. 450.0 mg.  
 Weight of one tablet Content of compound of formula l 450 mg. 250 mg.  
 We claim:  
 1. A compound represented by the formula wherein R, represents lower alkyl, lower alkenyl,  
 lower alkynyl, halo lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, lower alkylthio lower alkyl, lower alkylcarbonyl, halo lower alkylcarbonyl, lower alkanoyloxy lower alkyl, benzoyloxy lower alkyl, naphthoyloxy lower alkyl, lower alkyl benzoyloxy lower alkyl, lower alkyl naphthoyloxy lower alkyl pyridylcarbonyloxy lower alkyl. lower alkylaminocarbonyloxy lower alkyl,  
 wherein R and R each represent hydrogen or lower alkyl or R and R taken together with the nitrogen atom are aziridinyl, pyrrolidinyl. piperidinyl, azepinyl, thiazolidine, isoxazolidine, pyrazolidine, imidazolidine, oxazolidine. piperazinyl. morpholinyl, thiamorpholinyl, diazepinyl. thiazepinyl, oxazepinyl. lower alkyl or hydroxy lower alkyl substituted thiazolidine, isoxazolidine. pyrazolidine, imidazolidine. oxazolidine, piperazinyl. morpholinyl, thiamorpholinyl, diazepinyl, thiazepinyl. or oxazepinyl,  
 and n is l, 2, 3 or 4, R represents hydrogen, lower alkyl, lower alkenyl. lower alkynyl. lower alkoxy lower alkyl or hydroxy lower alkyl or R, and R taken together with the nitrogen atom is aziridinyl, pyrrolidinyl, azepinyl, thiazolidine, isoxazolidine, pyrazolidine, imidazolidine, oxazolidine, piperazinyl, morpholinyl, thiamorpholinyl, diazepinyl, thiazepinyl, oxazepinyl, lower alkyl or hydroxy lower alkyl substituted thiazolidine. isoxazolidine, pyrazolidine, imidazolidine, oxazolidine, piperazinyl, morpholinyl, thiamorpholinyl, diazepinyl, thiazepinyl or oxazepinyl, with the proviso that when R, represents lower alkyl and R represents hydrogen, the R, represents lower alkyl containing 2 to 7 carbon atoms,  
 and a pharmaceutically acceptable acid addition salt of the compounds which are basic.  
  2. A compound as defined in claim 1 wherein R, represents lower alkyl and R represents hydrogen or lower alkyl.  
  3, A compound as defined in claim 1 wherein R, represents wherein R R and n are as defined in claim I.  
  4. A compound as defined in claim 3 wherein R and R taken together with the nitrogen atom are piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl. lower alkyl or hydroxy lower alkyl substituted piperidinyl. piperazinyl, morpholinyl, or thiamorpholinyl and n is 2.  
  S. A compound as defined in claim 3 wherein R is hydrogen.  
  6. A compound as defined in claim 1 wherein R, is lower alkenyl, and R is hydrogen or lower alkyl.  
  7. A compound according to claim 1 which is l-(3,5- dinitro-2-thienyl)-aziridine.  
  8. A compound according to claim 1 which is 4-(3,5- dinitro-2-thienyl )-morpholine.  
  9. A compound according to claim 1 which is l-(3,5- dinitro-2-thienyl)-pyrrolidine.  
  10. A compound according to claim 1 which is 2- chloro-N-( 3,5-dinitro-2-thienyl )-acetamide.  
  11. A compound according to claim 1 which is 2- bromo-N-( 3 .5-dinitro-2-thienyl )-acetamide.  
  12. A compound according to claim 1 which is 4- chloro-N-( 3 ,S-dinitro-Z-thienyl )-butyramide.  
  13. A compound according to claim 1 which is 2- chloro-N-(3,5-dinitro-2-thienyl)-N-methyl-acetamide.  
  14. A compound according to claim 1 which is N-(2- chloroethyl)-3,5-dinitro-2-thiophenamine.  
  15. A compound according to claim I which is 4-[2- 3.5-dinitro-2-thienyl )-amino l-ethyl -morpholine.  
  16. A compound according to claim 1 which is N- isobutyl-3,5-dinitro-Z-thiophenamine.  
  17. A compound according to claim 1 which is N- secbutyl-3,5-dinitro-2-thiophenamine.  
  18. A compound according to claim 1 which is N- allyl-3.5-dinitro-2-thiophenamine.  
  19. A compound according to claim 1 which is N- isopropyl 3.S-dinitro-2-thiophenamine.  
  20. A compound according to claim 1 which is N- ethyl-3.5-dinitro-2-thiophenamine.  
  21. A compound according to claim 1, which is N- butyl-3,5-dinitro-2-thiophenamine.  
  22. A compound according to claim 1 which is N-(2- methoxyethyl)-3,5-dinitro-2-thiophenamine.  
  23. A compound according to claim 1 which is 2- [(3 .S-dinitrothienyl )-amino ]-ethanol.  
  24. A compound according to claim 1 which is N,N- dimethyl-3,5-dinitro-2-thiophenamine.  
  25. A compound according to claim 1 which is N- allyl-N-methyl-3,5-dinitro-2-thiophenamine.  
  26. A compound according to claim 1 which is N- isobutyl-N-methyl-3,5-dinitro-2-thiophenamine.  
  27. A compound according to claim 1 which is N- ethyl-N-methyl-3,5-dinitro-2-thiophenamine.  
  .28. A compound according to claim 1 which is 3- (3 ,5-dinitro-2-thienyl )-thiazolidine.  
  29. A compound according to claim 1 which is 2- (3.5-dinitro-2-thienyl)-isoxazolidine.  
  30. A compound according to claim 1 which is 4- (3 .5-dinitro-2-thienyl l -piperazine-ethanol.  
  31. A compound according to claim 1 which is l- (3 ,5-dinitro-2-thienyl )-4-methylpiperazine.  
  32. A compound according to claim 1 which is 2- (3 ,5-dinitro-2-thienyl)-tetrahydro-2H-1,2-oxazine.  
  33. A compound according to claim 1 which is N&#39;- (3 ,5-dinitro-2-thienyl )-N,N-diethylethylenediamine.  
  34. A compound according to claim 1 which is N- (3,5dinitro-2-thienyl )-N,N-diethyll ,3- propanediamine.  
  35. A compound according to claim 1 which is 2- [(3,5-dinitro-2-thienyl)-amino]-ethylmethylcarbamate.  
  36. A compound according to claim 1 which is 4- [(3,5-dinitro-2-thienyl)-amino]-l-butanol.  
  37. A compound according to claim 1 which is N-(2- methoxyethyl)-N-methyl-3,5-dinitro-2-thiophenamine.  
  38. A compound according to claim 1 which is N-(3- ethoxypropyl)-3,5-dinitro-2-thiopenamine.  
  39. A compound according to claim 1 which is N- (3,5-dinitro-2-thienyl)-N,N-dimethylethylenediamine.  
  40. A compound according to claim 1 which is l- [(3.5-dinitro-2-thienyl)-amino]-2-propanol.  
  41. A compound according to claim 1 which is 2- [(3,5-dinitro-2-thienyl)-amino]-ethyl isonicotinate.  
  42. A compound according to claim 1 which is N-(2- methylthio-ethyl )-3 ,S-dinitro-Z-thiophenamine.  
 43. A compound according to claim 1 which is 2- [(3,5-dinitro-2-thienyl)-amino]-ethyl acetate.  
 UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION 9 PATENT NO. 3 30 49 DATED April 29, 1975 INV ENTOR(S) Andre Szente and Joseph Hellerbach It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below: 0  
  4 Column 20, hnes 60-65, c1a1m 3, -N\ should be 5 4 9 (CH -N Column 22 line 32, &#34;thiopenamine&#34; should be thiophenamine Signed and Sealed this 0 fifteenth Day Of June 1976 i sum] 2 Arrest: Q RUTH C. MASON C. MARSHALL DANN Arresting Officer Commissioner ofParems and Trademarks Q t E